Summarized by Masters of Longevity from PR Newswire.
This article previews a conference presentation of final survival results from a Phase III clinical trial of a new targeted antibody–drug conjugate for EGFR‑mutant advanced non‑squamous lung cancer, explaining the trial context and what readers can expect to learn about efficacy and safety.
Key Takeaways
- Sacituzumab tirumotecan improved overall survival versus platinum doublet chemotherapy in EGFR-mutant NSCLC.
- Adjusting for later ADC use, sacituzumab tirumotecan reduced death risk by 43%.
- Sacituzumab tirumotecan had manageable side effects, mainly blood toxicity and stomatitis.
